SCHEMBL20139873

SCHEMBL20139873

CCC(CNCCCO)NS(=O)(=O)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
THRB P10828 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
F2 P00734 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42
PKM P14618 1/20 0.41
CYP19A1 P11511 1/20 0.41
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932987 1.00 CA1 (0.47) CA1CA2MMP1MMP2MMP9
SCHEMBL20139870 1.00 CA1 (0.47) CA1CA2MMP1MMP2MMP9
SCHEMBL14990726 0.86 CA1 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL14990725 0.86 CA1 (0.49) CA1CA2MMP1MMP2MMP9
SCHEMBL968534 0.83 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL20139557 0.83 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL968537 0.83 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL29933231 0.83 CA1 (0.56) CA1CA2MMP1MMP2MMP9
SCHEMBL23779401 0.83 CA1 (0.48) CA1CA2MMP1MMP2MMP9
SCHEMBL23779403 0.83 CA1 (0.48) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. 2024-11-21 US disclosed
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-20220363676-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. 2022-11-17 US disclosed
EP-3534899-B1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS INC (US) 2022-06-01 EP disclosed
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
EP-3534899-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE Corvus Pharmaceuticals, Inc. (US) 2019-09-11 EP disclosed
WO-2018089261-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase IL2, NFATC1, IL2RA CA1 3010/4885CA2 1859/4885MMP1 3421/4885
US-20220363676-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE IL2, NFATC1, IL2RA CA1 3010/4885CA2 1859/4885MMP1 3421/4885
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE IL2, NFATC1, IL2RA CA1 3010/4885CA2 1859/4885MMP1 3421/4885
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA CA1 3010/4885CA2 1859/4885MMP1 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.